How to effectively manage the event of bleeding complications when using anticoagulants

Expert Review of Hematology

Volumn 9, Issue 1, 2016, Pages 37-50

  Sartori, Maria Teresa ^a   Prandoni, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anticoagulation; Antidote; Bleeding; Direct oral anticoagulants; Fondaparinux; Heparin; Idrabiotaparinux; Prothrombin complex concentrates; Recombinant factor VIIa; Vitamin K antagonists

Indexed keywords

ANDEXANET ALFA; ANTICOAGULANT AGENT; ANTIVITAMIN K; CIRAPARANTAG; FONDAPARINUX; IDARUCIZUMAB; IDRABIOTAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTICOAGULATION; BLEEDING; HEMOSTASIS; HOSPITAL ADMISSION; HUMAN; MEDICAL DECISION MAKING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; HEMORRHAGE;

ANTICOAGULANTS; HEMORRHAGE; HUMANS;

EID: 84947281434     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2016.1112733     Document Type: Review

References (87)

1. Landefeld CS, Beyth RJ. Anticoagulantrelated bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95(3):315-328.
2. Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002-2012.
3. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost. 2005;3:692-694.
4. Schulman S, Angerås U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202-204.
5. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962.
6. Van der Hulle T, Kooiman J, Den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and metaanalysis. J Thromb Haemost. 2014;12(3):320-328.
7. Van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968-1975.
8. Hashash JG, Shamseddeen W, Skoury A, et al. Gross lower gastrointestinal bleeding in patients on anticoagulant and/or antiplatelet therapy: endoscopic findings, management, and clinical outcomes. J Clin Gastroenterol. 2009;43(1):36-42.
9. Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endosc. 2003;58(3):369-373.
10. Avidor Y, Nadu A, Matzkin H. Clinical significance of gross hematuria and its evaluation in patients receiving anticoagulant and aspirin treatment. Urology. 2000;55(1):22-24.
11. Clemens A, Strack A, Noack H, et al. Anticoagulant-related gastrointestinal bleeding - could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med. 2014;46(8):672-678.
12. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease - antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl. 2):e419S-e494S.
13. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med. 1993;119(9):874-881.
14. Smith SB, Geske JB, Maguire JM, et al. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest. 2010;137(6):1382-1390.
15. Prandoni P, Carnovali M, Marchiori A, Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med. 2004;164(10):1077-1083.
16. Nybo M, Madsen JS. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol. 2008;103(2):192-196.
17. Laposata M, Green D, Van Cott EM, et al. College of American Pathologists-conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of lowmolecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122(9):799-807.
18. Lim W, Dentali F, Eikelboom JW, et al. Metaanalysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673-684. • Relevant meta-analysis pointing out the crucial role of severe renal failure in increasing the risk of bleeding complications in patients treated with lowmolecular-weight heparins.
19. Spinler SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146(1):33-41.
20. Cestac P, Bagheri H, Lapeyre-Mestre M, et al. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Saf. 2003;26(3):197-207.
21. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106(20):2550-2554.
22. Elmer J, Wittels KA. Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature. Transfus Med. 2012;22(2):108-115.
23. Luporsi P, Chopard R, Janin S, et al. Use of recombinant factor VIIa (NovoSeven (®)) in 8 patients with ongoing lifethreatening bleeding treated with fondaparinux. Acute Card Care. 2011;13(2):93-98.
24. Vavra KA, Lutz MF, Smythe MA. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants. Ann Pharmacother. 2010;44(4):718-726.
25. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost. 2011;9(1):92-99.
26. Büller HR, Gallus AS, Pillion G, et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012;379(9811):123-129.
27. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423-428.
28. Roskell NS, Samuel M, Noack H, et al. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace. 2013;15(6):787-797.
29. Ost D, Tepper J, Mihara H, et al. Duration of anticoagulation following venous thromboembolism: a metaanalysis. JAMA. 2005;294:706-715.
30. Garcia D, Crowther MA, Ageno W. Practical management of coagulopathy associated with warfarin. BMJ. 2010;340:c1813.
31. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy - antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl. 2):e152S-e184S. • Clinical practice guidelines outlining the evidence-based management of anticoagulant treatment with vitamin K antagonists and parenteral anticoagulants; reversal strategies for vitamin K antagonist-related major bleeding with vitamin K and prothrombin complex concentrates are reported.
32. Makris M, Van Veen JJ, Tait CR, et al. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2013;160(1):35-46. •• Extended practice guidelines on the management of bleeding complications occurring while taking several antithrombotic drugs, including anticoagulants, antiplatelets and fibrinolytic agents. General measures and antithrombotic drug-specific indications are detailed.
33. Patriquin C, Crowther M. Treatment of warfarin-associated coagulopathy with vitamin K. Expert Rev Hematol. 2011;4:657-665.
34. Hickey M, Gatien M, Taljaard M, et al. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation. 2013;128(4):360-364.
35. Holland LL, Nrooks JP. Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results. Am J Clin Pathol. 2006;126:133-139.
36. Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137-143.
37. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transf. 2010;8:149-154.
38. Voils SA, Baird B. Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter. Thromb Res. 2012;130:833-840.
39. Tran HA, Chunilal SD, Harper PL, et al.; Australasian Society of Thrombosis and Haemostasis (ASTH). An update of consensus guidelines for warfarin reversal. Med J Aust. 2013;198(4):198-199.
40. Keeling D, Baglin T, Tait C, et al.; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011;154(3):311-324.
41. Pernod G, Godiér A, Gozalo C, et al.; French National Authority for Health. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding. Thromb Res. 2010;126(3):e167-74.
42. National Advisory Committee on Blood and Blood products. Recommendations for use of prothrombin complex concentrates in Canada [Internet]. 2014 [cited 2014 May 16]. Available from: http://www.nacblood. ca/resources/guidelines/PCC-Recommendations-Final-2014-05-16.pdf
43. Makris M, Watson HG. The management of coumarin-induced anticoagulation annotation. Br J Haematol. 2001;114(2):271-280.
44. Van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;118(3):313-320.
45. Khorsand N, Kooistra HA, van Hest RM, et al. A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy. Thromb Res. 2015;135(1):9-19. •• Interesting recent review on 28 studies, including four randomized trials, reporting the use of prothrombin complex concentrates for emergency vitamin K antagonist reversal. The authors demonstrated that dosing strategies were not uniform among studies, but without evidence of superiority; in addition, they observed that a predefined prothrombin complex concentrate dosing protocol appeared to be essential in emergency vitamin K antagonist reversal.
46. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasmacontrolled, phase IIIb study. Circulation. 2013;128(11):1234-1243.
47. Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, noninferiority, randomised trial. Lancet. 2015;385(9982):2077-2087.
48. Tazarourte K, Riou B, Tremey B, et al. Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study). Critical Care. 2014;18:R81.
49. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37(6):1465-1470.
50. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824-836.
51. Parry-Jones AR, Di Napoli M, Goldstein JN, et al. Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. Ann Neurol. 2015;78(1):54-62.
52. Karaca MA, Erbil B, Ozmen MM. Use and effectiveness of prothrombin complex concentrates vs fresh frozen plasma in gastrointestinal hemorrhage due to warfarin usage in the ED. Am J Emerg Med. 2014;32:660-664.
53. Radaelli F, Dentali F, Repici A, et al. Management of anticoagulation in patients with acute gastrointestinal bleeding. Dig Liver Dis. 2015;47(8):621-627.
54. Dentali F, Marchesi C, Giorgi Pierfranceschi M, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: a meta-analysis. Thromb Haemost. 2011;106(3):429-438. • Meta-analysis evaluating the risk of thrombotic complications using threefactor and four-factor prothrombin complex concentrates for reversal of vitamin K antagonists, demonstrating that the risk is quite low but deserves attention.
55. Sorensen B, Johansen P, Nielsen GL, et al. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis. 2003;14:469-472.
56. Levi M, Peters M, Buller HR, et al. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33:883-890.
57. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293-298.
58. Heidbuchel H, Verhamme P, Alings M, et al.; European Heart Rhythm Association. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625-651. •• Very extensive and detailed guide for managing patients taking direct oral anticoagulants in clinical practice. Strategies for the management of minor, major and life-threatening bleeding are suggested, including the use of prothrombin complex concentrates, activated prothrombin complex concentrates and recombinant factor VIIa.
59. Pernod G, Albaladejo P, Godier A, et al.; Working Group on Perioperative Haemostasis. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP). Arch Cardiovasc Dis. 2013;106(6-7):382-93. • Practical proposals on the laboratory and medical approach to patients on dabigatran or rivaroxaban presenting with major hemorrhage or urgent surgical need requiring anticoagulation reversal.
60. Liew A, Eikelboom JW, O'Donnell M, et al. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. Can J Cardiol. 2013;29(Suppl. 7):S34-44.
61. Tran H, Joseph J, Young L, et al. New oral anticoagulants: a practical guide on prescription, laboratory testing and periprocedural/bleeding management. Australasian Society of Thrombosis and Haemostasis. Intern Med J. 2014;44(6):525-536.
62. Vilchez JA, Gallego P, Lip GYH. Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf. 2014;5(1):8-20.
63. Gherie E, Tormey C. Novel oral anticoagulants - efficacy, laboratory measurement, and approaches to emergent reversal. Arch Pathol Lab Med. 2015;139:687-692.
64. Crowther M, Crowther MA. Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol. 2015;35(8):1736-1745.
65. Vanryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. ThrombHaemost. 2010;103(6):1116-1127.
66. Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014;14:147-154.
67. Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. ThrombHaemost. 2012;107:838-847.
68. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. ThrombHaemost. 2010;104:1263-1271.
69. Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259-268.
70. Warkentin TE, Margetts P, Connolly SJ, et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012;119:2172-2174.
71. Siegal D. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis. 2015;39:395-402.
72. Weitz J, Quinlan D, Eikelboom J. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 2012;126:2428-2432.
73. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J ThrombHaemost. 2012;10:1478-1485.
74. Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128(21):2325-2332.
75. Piccini JP, Garg J, Patel MR, et al.; ROCKET AF Investigators. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35(28):1873-1880.
76. Held C, Hylek EM, Alexander JH, et al Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015;36:1264-1272.
77. Beyer-Westendorf J, Ebertz F, Förster K, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. ThrombHaemost. 2015;113(6):1247-1257.
78. Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955-962.
79. Masotti L, Lorenzini G, Seravalle C, et al. Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. J Thromb Thrombolysis. 2015;39(4):427-433.
80. Gomez-Outes A, Suarez-Gea ML, Lecumberri R, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10. • Detailed review on the ongoing research on new antidotes for anticoagulant drugs.
81. Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace. 2015. DOI:10.1093/europace/euv030.
82. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. ThrombHaemost. 2015;113(5):931-942.
83. Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. [cited 2015 Jun. 15]. DOI:10.1016/S0140-6736 (15) 60732-2.
84. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511-520. • Interim analysis of an ongoing trial in dabigatran-treated patients with urgent need of anticoagulation reversal. Promising results on the efficacy and safety of the new antidote idarucizumab are presented.
85. Crowther MA, Lu G, Conley P, et al. Sustained reversal of apixaban anticoagulation with andexanet alpha using a bolus plus infusion regimen in a phase II placebo controlled trial [abstract]. Eur Heart J. 2014;35:137.
86. Bakhru S, Laulicht B, Jiang X, et al. Reversal of anticoagulant-induced bleeding in external and internal bleeding models by PER977, a small molecule anticoagulant antidote. Circulation. 2014;130:A19361. (abstract).
87. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141-2142.